http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006119168-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_773f1212c89503aa4d44643c5b64fa70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cffb44082220de55d755db0cc471fd4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78f6302b5d69a781eb0587179caafaf6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate | 2006-05-02^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9760faa66b665815275a16483bb7ca9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6de719a48c2f1678a118b4642112506d |
| publicationDate | 2007-01-25^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2006119168-A3 |
| titleOfInvention | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors |
| abstract | Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy. |
| priorityDate | 2005-05-02^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 40 of 40.